Variables | ICC, Status Score, Wk 0 (95% CI) | ICC, Change Score, wks 0–24 (95% CI) | SDC | GRI, Wk 6 | SRM, Wk 6, ADA/PBO | SRM, Wk 24, Both Groups | SRM, Wk 48, Both Groups |
---|---|---|---|---|---|---|---|
No. patients | 8 | 8 | 8 | 47 | 47 | 44 | 39 |
Peripheral joint indices | |||||||
Synovitis | 0.45 (−0.42 to 0.86) | 0.13 (−0.44 to 0.70) | 1.3 | 0.16 | 0.08/(−0.12 | 0.06 | 0.14 |
BME | 0.43 (−0.33 to 0.85) | 0.52 (−0.32 to 0.88) | 1.0 | 0.43 | 0.15/(−0.30 | 0.32 | 0.22 |
Inflammation | 0.67 (−0.03 to 0.93) | 0.25 (−0.47 to 0.78) | 2.0 | 0.26 | 0.13/(−0.19 | 0.19 | 0.22 |
Enthesis indices | |||||||
BME | 0.71 (0.14(−0.93) | 0.86 (0.45(−0.97) | 1.4 | 1.10 | 0.45/(−0.21 | 0.27 | 0.20 |
Soft tissue inflammation | 0.34 (−0.34 to 0.81) | 0.33 (−0.20 to 0.79) | 1.6 | 0.34 | 0.33/(−0.26 | 0.20 | 0.11 |
Inflammation | 0.73 (0.08–0.94) | 0.82 (0.37–0.96) | 1.8 | 0.61 | 0.44/(−0.29 | 0.29 | 0.19 |
Axial BME | 0.91 (0.62–0.98) | 0.67 (−0.06 to 0.92) | 2.7 | 0.96 | 0.63/0.14 | 0.71 | 0.62 |
Total BME | 0.96 (0.79–0.99) | 0.91 (0.61–0.98) | 2.2 | 1.32 | 0.82/0.03 | 0.86 | 0.72 |
Total inflammation | 0.93 (0.69–0.99) | 0.85 (0.37–0.97) | 2.3 | 1.07 | 0.65/(−0.17 | 0.83 | 0.70 |
SDC: smallest detectable change; WBMRI: whole-body magnetic resonance imaging; GRI: Guyatts responsiveness index; ADA: adalimumab; PBO: placebo; SRM: standardized response mean; BME: bone marrow edema.